ClinicalTrials.gg
Active, not recruitingNCT06288451Updated Jun 2, 2025

DePTH: De-emphasize PTH

A Phase 2 interventional study of Oral calcitriol with cinacalcet rescue and IV activated vitamin D in Kidney Failure, Chronic and Chronic Kidney Disease-Mineral and Bone Disorder, sponsored by University of Washington. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-02.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Kidney Failure, Chronic by University of Washington — 1 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · University of Washington.

Planned enrollment
10th of 15
90 · median 120
Started
2024
the only one that year
Phase 2
3 of 18
none open now
Registered
17th of 18
by date

Among the 18 studies in Kidney Failure, Chronic by University of Washington, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 17th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

1 of the 18 studies in Kidney Failure, Chronic by University of Washington is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Kidney Failure, Chronic by University of Washington, or all of them as a file.
02

Study summary

The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the hypothesis that low fixed-dose oral calcitriol (intervention) will have more favorable effects on a comprehensive panel of biomarkers that assesses mineral metabolism, bone turnover, and serum calcification propensity, compared with variably-dosed intravenous activated vitamin D titrated to PTH targets (usual care).

Read the detailed description

Because of the kidneys' major role in vitamin D metabolism, most patients with kidney failure on dialysis have biochemical abnormalities that include vitamin D deficiency and high levels of phosphate, fibroblast growth factor-23 (FGF-23), and parathyroid hormone (PTH). All of these abnormalities are associated with cardiovascular disease, bone disease, and death and are major reasons why nephrologists have treated patients on dialysis with activated vitamin D agents for over 30 years. Current guidelines, however, encourage nephrologists to use high doses of vitamin D in order to lower PTH levels to pre-specified treatment targets. This approach to treatment has not been proven to improve health and survival, and may be associated with several harms, including further increasing levels of FGF-23 (a major cardiovascular risk factor), increasing calcium levels, which may promote vascular calcification, low turnover bone disease, and interruptions in vitamin D treatments.

Administering a low, stable dose of vitamin D may be safer and more effective than the current standard of care. The De-emphasize PTH (DePTH) Study is a pragmatic randomized clinical trial of 90 patients on hemodialysis in Seattle, WA, USA that tests whether a low fixed-dose of oral calcitriol (the active form of vitamin D; study intervention) is more safe, effective, and feasible compared with the current usual care. Participants will be recruited at their hemodialysis treatment centers and randomized in a 1:1 ratio to one of these two treatment strategies and followed over 12 months. Participants randomized to the study intervention will receive a fixed dose of calcitriol 0.5 mcg three times a week at their dialysis treatment sessions regardless of PTH level over the ensuing 12 months. Participants randomized to usual care will maintain the existing approach to treating abnormal mineral metabolism using vitamin D doses titrated to monthly to quarterly measurements of PTH. The outcomes for this trial are a panel of blood-based measurements of bone and vascular health that will be drawn at the same time as the blood work done monthly as part of routine dialysis care.

03

Conditions studied

  • Kidney Failure, Chronic
  • Chronic Kidney Disease-Mineral and Bone Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >=18 years
  2. Kidney failure treated with in-center hemodialysis
  3. PTH >=150 pg/mL x 2 consecutive measures at least 1 month apart or active IV activated vitamin D treatment using the NKC protocol

Exclusion criteria

Exclusion Criteria:

  1. History of parathyroidectomy or calciphylaxis
  2. Severe secondary hyperparathyroidism (PTH >=600 pg/mL x 2 consecutive measures at least 1 month apart despite paricalcitol >=10 mcg 3x/week or doxercalciferol >=5 mcg 3x/week or cinacalcet >30 mg/d)
  3. Calcium >9.8 mg/dL
  4. Phosphate >9 mg/dL
  5. Cholestyramine, phenytoin/phenobarbital, or ketoconazole use
  6. Breast-feeding mothers
  7. Inability to provide and no legally authorized representative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Low dose oral calcitriol

    Drug: Oral calcitriol with cinacalcet rescue

  • Active comparator
    Usual care

    Drug: IV activated vitamin D

Interventions

  • DrugOral calcitriol with cinacalcet rescue

    Participants will receive in-center oral calcitriol at a fixed dose of 0.5 mcg three times weekly at their dialysis treatment sessions regardless of their parathyroid hormone (PTH) concentrations over the 12-month trial period. Only if their serum PTH exceeds 800 pg/mL over 2 consecutive measurements will they be started on cinacalcet at 30 mg/d in order to protect against severe unremitting hyperparathyroidism.

  • DrugIV activated vitamin D

    Participants will continue to receive intravenously-administered activated vitamin D per the Northwest Kidney Center treatment protocol, dose-titrated to monthly to quarterly parathyroid hormone concentrations.

06

What researchers measure

Primary outcomes

  1. Change in fibroblast growth factor-23

    Change in fibroblast growth factor-23

    Time frame: 12 months

Secondary outcomes

  1. Change in serum calcium

    Change in serum calcium

    Time frame: 12 months

  2. Change in serum phosphate

    Change in serum phosphate

    Time frame: 12 months

  3. Change in serum bone-specific alkaline phosphatase

    Change in serum bone-specific alkaline phosphatase

    Time frame: 12 months

  4. Change in serum parathyroid hormone

    Change in serum parathyroid hormone

    Time frame: 12 months

  5. Change in T50 test of serum calcification propensity

    Change in T50 test of serum calcification propensity

    Time frame: 12 months

Other outcomes

  1. Patient acceptability

    Study acceptability to patients rated from 1 to 5 with 1 being the lowest acceptability and 5 being the highest

    Time frame: 6 months

  2. Patient acceptability

    Study acceptability to patients rated from 1 to 5 with 1 being the lowest acceptability and 5 being the highest

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

Of 41 non-industry phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 35 months is close to that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 1, 2024
StartActual
Mar 11, 2024
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Jun 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06288451
Responsible party
Simon Hsu, MD, MS (Assistant Professor, University of Washington) — Principal investigator
First posted
Mar 1, 2024
Start date
Mar 11, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jun 2, 2025

Study contacts

Simon Hsu, MD, MS
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion